PMID- 30077691
OWN - NLM
STAT- MEDLINE
DCOM- 20181214
LR  - 20181214
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 144
DP  - 2018 Oct
TI  - Perceptions and experiences of adult patients with type 1 diabetes using 
      continuous subcutaneous insulin infusion therapy: Results of an online survey.
PG  - 42-50
LID - S0168-8227(18)30399-1 [pii]
LID - 10.1016/j.diabres.2018.07.035 [doi]
AB  - AIMS: To assess perceptions of patients using subcutaneous insulin infusion 
      (CSII) about metabolic control, pump malfunctions, technical and insertion site 
      adverse events (AEs) related to infusion sets/catheters as well as patients' 
      practices. METHODS: Online survey (from June 2016 to January 2017) using an 
      actualized 39-item questionnaire directed to adults with type 1 diabetes (T1D) 
      using CSII therapy and living in the province of Quebec, Canada. RESULTS: 
      Participants with T1D (n = 115, 72% females, 39.7 +/- 14.0 years, diabetes 
      duration: 20.9 +/- 12.2 years, CSII use: 6.2 +/- 4.1 years) adequately completed the 
      survey. Infusion sets were changed every 3.3 +/- 0.9 day. Improved glucose control 
      and decreased number/severity of hypoglycemic episodes were reported by 80% and 
      68%/50% of subjects, respectively. Over the past year of CSII use, participants 
      perceived no increase in anxiety/worry (84%), no negative impact on life (89%) or 
      on time off from work/school (82%). Conversely, many experienced at least one 
      clinical AEs at insertion site [pain (84%), adhesion (76%), irritation (69%), 
      lipodystrophy (45%)] and technical issues [blockage (52%), cannula kinking (50%), 
      pump stop (55%), air bubbles (46%)]. No significant association was observed 
      between catheter wear-time and AEs. All participants had one or more problems 
      related to CSII use, although only 37% reported addressing these issues with 
      health professionals. CONCLUSION: Our study suggests that patients positively 
      perceived CSII use although they experienced a high frequency of clinical and 
      technical AEs. This warrants further attention by health professionals, 
      investigators and manufacturers to optimize CSII therapy.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Taleb, Nadine
AU  - Taleb N
AD  - Institut de recherches cliniques de Montreal, 110, avenue des Pins Ouest, 
      Montreal, Quebec H2W 1R7, Canada; Department of Biomedical Sciences, Faculty of 
      Medicine, Universite de Montreal, 2900, Edouard-Montpetit, Montreal, Quebec H3T 
      1J4, Canada.
FAU - Messier, Virginie
AU  - Messier V
AD  - Institut de recherches cliniques de Montreal, 110, avenue des Pins Ouest, 
      Montreal, Quebec H2W 1R7, Canada.
FAU - Ott-Braschi, Sylvie
AU  - Ott-Braschi S
AD  - Institut de recherches cliniques de Montreal, 110, avenue des Pins Ouest, 
      Montreal, Quebec H2W 1R7, Canada; Centre Hospitalier de l'Universite de Montreal, 
      3840, rues Saint-Urbain, Montreal, Quebec H2W 1T8, Canada.
FAU - Ardilouze, Jean-Luc
AU  - Ardilouze JL
AD  - Department of Medicine, Faculty of Medicine and Health Sciences, Universite de 
      Sherbrooke, 3001-12(e) Avenue Nord, Sherbrooke, Quebec J1H 5N4, Canada.
FAU - Rabasa-Lhoret, Remi
AU  - Rabasa-Lhoret R
AD  - Institut de recherches cliniques de Montreal, 110, avenue des Pins Ouest, 
      Montreal, Quebec H2W 1R7, Canada; Centre Hospitalier de l'Universite de Montreal, 
      3840, rues Saint-Urbain, Montreal, Quebec H2W 1T8, Canada; Department of 
      Nutrition, Faculty of Medicine, Universite de Montreal, 2405, chemin de la 
      Cote-Sainte-Catherine, Montreal, Quebec H3T 1A8, Canada; Montreal Diabetes 
      Research Center, 900 Saint-Denis, Montreal, Quebec H2X 0A9, Canada. Electronic 
      address: remi.rabasa-lhoret@ircm.qc.ca.
LA  - eng
PT  - Journal Article
DEP - 20180802
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Canada/epidemiology
MH  - Diabetes Mellitus, Type 1/*drug therapy/epidemiology/*psychology
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Injections, Subcutaneous
MH  - Insulin/*administration & dosage
MH  - *Insulin Infusion Systems
MH  - Male
MH  - Perception
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Continuous subcutaneous insulin infusion
OT  - Insulin catheters
OT  - Insulin infusion set
OT  - Insulin pumps
OT  - Survey
OT  - Type 1 diabetes
EDAT- 2018/08/06 06:00
MHDA- 2018/12/15 06:00
CRDT- 2018/08/06 06:00
PHST- 2018/03/26 00:00 [received]
PHST- 2018/06/28 00:00 [revised]
PHST- 2018/07/30 00:00 [accepted]
PHST- 2018/08/06 06:00 [pubmed]
PHST- 2018/12/15 06:00 [medline]
PHST- 2018/08/06 06:00 [entrez]
AID - S0168-8227(18)30399-1 [pii]
AID - 10.1016/j.diabres.2018.07.035 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2018 Oct;144:42-50. doi: 10.1016/j.diabres.2018.07.035. 
      Epub 2018 Aug 2.